Vir Biotechnology (VIR) Net Income towards Common Stockholders (2018 - 2025)
Historic Net Income towards Common Stockholders for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to -$163.1 million.
- Vir Biotechnology's Net Income towards Common Stockholders rose 2366.49% to -$163.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$499.7 million, marking a year-over-year increase of 631.69%. This contributed to the annual value of -$522.0 million for FY2024, which is 1513.69% up from last year.
- As of Q3 2025, Vir Biotechnology's Net Income towards Common Stockholders stood at -$163.1 million, which was up 2366.49% from -$111.0 million recorded in Q2 2025.
- Vir Biotechnology's 5-year Net Income towards Common Stockholders high stood at $525.3 million for Q4 2021, and its period low was -$213.7 million during Q3 2024.
- In the last 5 years, Vir Biotechnology's Net Income towards Common Stockholders had a median value of -$111.0 million in 2025 and averaged -$25.7 million.
- Per our database at Business Quant, Vir Biotechnology's Net Income towards Common Stockholders soared by 54975.38% in 2021 and then tumbled by 22374.9% in 2022.
- Vir Biotechnology's Net Income towards Common Stockholders (Quarter) stood at $525.3 million in 2021, then crashed by 119.34% to -$101.6 million in 2022, then fell by 14.14% to -$116.0 million in 2023, then rose by 9.82% to -$104.6 million in 2024, then crashed by 55.98% to -$163.1 million in 2025.
- Its last three reported values are -$163.1 million in Q3 2025, -$111.0 million for Q2 2025, and -$121.0 million during Q1 2025.